Annovis BioANVS
ANVS
About: Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
Employees: 6
0
Funds holding %
of 6,815 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
175% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 4
71% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 7
67% more capital invested
Capital invested by funds: $5.7M [Q2] → $9.53M (+$3.83M) [Q3]
13% more funds holding
Funds holding: 31 [Q2] → 35 (+4) [Q3]
0.2% more ownership
Funds ownership: 8.86% [Q2] → 9.06% (+0.2%) [Q3]
72% less call options, than puts
Call options by funds: $3.33M | Put options by funds: $12M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$21
350%
upside
Avg. target
$24
419%
upside
High target
$30
542%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert 39% 1-year accuracy 71 / 182 met price target | 350%upside $21 | Buy Maintained | 11 Nov 2024 |
HC Wainwright & Co. Raghuram Selvaraju 40% 1-year accuracy 125 / 312 met price target | 542%upside $30 | Buy Reiterated | 11 Nov 2024 |
Maxim Group Jason McCarthy 39% 1-year accuracy 11 / 28 met price target | 435%upside $25 | Buy Upgraded | 25 Oct 2024 |
EF Hutton Jason Kolbert 39% 1-year accuracy 71 / 182 met price target | 350%upside $21 | Buy Maintained | 15 Oct 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
19 hours ago
Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection
MALVERN, Pa, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it was granted the U.S. patent covering methods for the treatment and prevention of acute brain or nerve injuries using buntanetap.
Neutral
GlobeNewsWire
1 month ago
Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace
LOS ANGELES, Dec. 05, 2024 (GLOBE NEWSWIRE) -- via IBN -- InvestorBrandNetwork, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce Annovis Bio's (NYSE: ANVS) recent feature on Today's Marketplace (TMP) as part of its commitment to amplifying industry leaders' voices through targeted distribution channels.
Neutral
PRNewsWire
1 month ago
/C O R R E C T I O N -- Today's Marketplace/
In the news release, Annovis CEO Discusses Breakthrough Drug for Neurodegenerative Diseases on Today's Marketplace, issued 04-Dec-2024 by Today's Marketplace over PR Newswire, we are advised by the company that in the Annovis boilerplate, the first sentence should include the stock ticker (NYSE: ANVS) as originally issued inadvertently. The complete, corrected release follows: Annovis CEO Discusses Breakthrough Drug for Neurodegenerative Diseases on Today's Marketplace NEW YORK , Dec. 4, 2024 /PRNewswire/ -- Today's Marketplace (TMP) is proud to announce a featured interview with Annovis' Founder, President and CEO, Maria Maccecchini, PHD, and Scott Shipman, MD, MPH, Executive Director for Creighton University's Institute for Population Health.
Neutral
GlobeNewsWire
1 month ago
Annovis to Host Year-End Investor Webcast on December 11, 2024
MALVERN, Pa., Nov. 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, is pleased to announce a live investor webcast scheduled for December 11, 2024, at 4:30 PM EST.
Neutral
GlobeNewsWire
2 months ago
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio
LOS ANGELES, Oct. 31, 2024 (GLOBE NEWSWIRE) -- via IBN -- IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.
Neutral
GlobeNewsWire
3 months ago
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs
MALVERN, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), announced today the successful outcome of the End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on October 10, 2024. During the meeting, the FDA granted clearance to proceed with pivotal Phase 3 studies, based on the Company's Phase 2/3 clinical data showing symptomatic improvement in early AD patients. Annovis and the FDA have now aligned on a development path for buntanetap towards the filing of New Drug Applications (NDAs), one for short-term and one for long-term efficacy.
Neutral
GlobeNewsWire
3 months ago
Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases
NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Annovis Bio Inc. (NYSE: ANVS) announces the availability of a broadcast titled, “Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition.”
Neutral
GlobeNewsWire
3 months ago
Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations
NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- via InvestorWire — Annovis Bio Inc. (NYSE: ANVS) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 60+ brands within the Dynamic Brand Portfolio @ IBN ( InvestorBrandNetwork ), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
Neutral
GlobeNewsWire
4 months ago
Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference
MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing novel therapies for neurodegenerative diseases, today announced that Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio, will participate in the H.C. Wainwright 26th Annual Global Investment Conference, held both virtually and in person at the Lotte New York Palace Hotel in New York City, September 9-11, 2024.
Neutral
GlobeNewsWire
5 months ago
Annovis' Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist
MALVERN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced new preclinical data demonstrating the synergistic effect of its lead compound, buntanetap, when combined with the glucagon-like peptide 1 (GLP-1) agonist dulaglutide (Trulicity®) in a mouse model of Alzheimer's disease.
Charts implemented using Lightweight Charts™